Thrombocytosis Diagnosis and Management

Primary Thrombocytosis

The American Society of Hematology recommends that primary thrombocytosis, which includes essential thrombocythemia (ET), polycythemia vera, and primary myelofibrosis, be diagnosed based on the presence of clonal markers such as JAK2V617F, CALR, or MPL mutations, with a high thrombotic risk associated with these conditions 1
Essential thrombocythemia (ET) is the most common primary cause of thrombocytosis, accounting for 45% of primary thrombocytosis cases, and is characterized by sustained platelet count ≥450 × 10⁹/L with bone marrow showing megakaryocytic proliferation and JAK2V617F or other clonal markers 1
Polycythemia vera presents with elevated platelets alongside increased red cell mass and often leukocytosis, and is associated with lower erythrocyte sedimentation rate, lower fibrinogen levels, and lower serum potassium 2, 3

Chronic inflammatory disorders, such as connective tissue diseases and inflammatory bowel disease, can cause secondary thrombocytosis, with elevated acute phase reactants and evidence of underlying inflammatory or infectious process 1
Iron deficiency anemia is a frequently overlooked but common cause of secondary thrombocytosis, accounting for 11% of cases 1
Malignancy, including solid tumors and lymphoproliferative disorders, can also cause secondary thrombocytosis, with elevated leukocyte count and evidence of underlying malignant process 1

The diagnostic algorithm for thrombocytosis involves confirming true thrombocytosis, obtaining complete blood count with differential, assessing for obvious secondary causes, and obtaining molecular testing for JAK2V617F, CALR, and MPL mutations if no clear secondary cause is identified or platelet count >1000 × 10⁹/L 1
Bone marrow biopsy is recommended to confirm diagnosis and exclude other myeloid neoplasms if molecular markers are positive or clinical suspicion is high for myeloproliferative neoplasm (MPN) 1

Other myeloproliferative disorders include polycythemia vera, primary myelofibrosis, and chronic myeloid leukemia, according to the Mayo Clinic Proceedings 4

Hemolytic anemia and post-hemorrhagic states can cause secondary thrombocytosis, as reported by Praxis Medical Insights 5
Post-splenectomy or functional hyposplenism can also cause secondary thrombocytosis, as reported by Praxis Medical Insights 5
Rebound thrombocytosis after treatment of thrombocytopenia can occur, as reported by Praxis Medical Insights 5
Pregnancy and hormonal influences can cause secondary thrombocytosis, as reported by Praxis Medical Insights 5
Exercise-induced thrombocytosis can be transient, as reported by Praxis Medical Insights 5

Laboratory artifacts can cause falsely low platelet counts, which must be distinguished from true thrombocytopenia, as reported by Praxis Medical Insights 6
In conditions with increased hematocrit, standard amounts of anticoagulant with reduced plasma volume can cause falsely low platelet counts, as reported by Praxis Medical Insights 6

Complete blood count with differential can help identify isolated thrombocytosis versus other cytopenias, as reported by Praxis Medical Insights 5
Peripheral blood smear examination can help exclude pseudothrombocytopenia and identify abnormalities, as reported by Praxis Medical Insights 5
Patient history can help identify potential secondary causes, as reported by Praxis Medical Insights 5

The National Comprehensive Cancer Network recommends classifying primary thrombocytosis as a clonal disorder in myeloproliferative neoplasms (MPNs), which includes essential thrombocythemia, polycythemia vera, primary myelofibrosis, and chronic myeloid leukemia 7

In children with empyema, a platelet count > 500 × 10⁹/L is observed in ≈ 93 % of cases; the count peaks around 2 weeks after onset and returns to normal by ≈ 3 weeks, and the condition is clinically benign, requiring no antiplatelet therapy. [8][9] (observational cohort, Thorax 2005)
A pooled analysis of six studies comprising 1,007 children with secondary thrombocytosis from diverse causes reported zero thrombotic events, indicating an extremely low thrombotic risk in this population. [8][9] (retrospective series, Thorax 2005)

Antiplatelet agents (e.g., aspirin) should not be initiated for secondary/reactive thrombocytosis, even when platelet counts exceed 500 × 10⁹/L, because they provide no benefit and increase bleeding risk. [8][9] (clinical guideline derived from Thorax 2005 data)

In patients presenting with Budd‑Chiari syndrome or portal vein thrombosis, myeloproliferative neoplasms (MPNs) are identified in 30–40 % of cases, underscoring the need for systematic evaluation for an underlying clonal disorder. 10 (prospective cohort, Journal of Hepatology 2016)
For splanchnic vein thrombosis, the typical thrombocytosis that would suggest an MPN may be masked by hypersplenism and hemodilution; therefore, JAK2V617F mutation testing (and other MPN‑specific molecular assays) is recommended to avoid missed diagnoses. 10 (clinical recommendation, Journal of Hepatology 2016)